Connect Biopharma Holdings Ltd (CNTB)

Connect Biopharma Holdings Ltd (CNTB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $56.7M; returns 1 day +0.6%, 1 week -15.4%, 1 year -52.7%.

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company specializing in the development of next-generation therapies for T cell-driven inflammatory diseases. The company's economic engine is primarily driven by its lead product candidate, rademikibart (formerly CBP-201), a human monoclonal antibody targeting the IL-4Rα receptor.

Groups CNTB belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage Biotech
• Clinical Stage Biopharma
• Monoclonal Antibodies
• Chronic Inflammatory Diseases
• Clinical Stage
• Autoimmune Diseases
• Dermatology
• Healthcare

CNTB financial model: income statement, cash flow and balance sheet